November has been a promising month for CytoSorbents Corp. (NASDAQ: CTSO), a critical care immunotherapy company. The New Jersey-based company, specializing in blood purification to control deadly inflammation in critically ill and cardiac surgery patients, reported its financial results for the third quarter ended September 30, 2016.
CTSO reported that product sales for the third quarter of this year were up to $2.14 million, a new record, marking the sixth quarter in a row to show substantial growth with sales up by 100% from 2015’s $1.07 million. The jump was attributed to increases in both direct sales and sales through distributors.
Total revenue for the third quarter of 2016, including product sales and grant revenue, came in at $2.4 million, marking an overall gross margin of $1.4 million compared to $0.7 million in the third quarter of 2015. In addition, product gross margins for the third quarter of 2016 were approximately 5% higher than in the same quarter of 2015.
As a result, Aegis Capital Corp. upgraded its CytoSorbents estimates, offering the company a ‘Buy’ rating with a target price of $20. The report states: “CTSO reported revenues of $2.41 million versus consensus of $2.21 million and our $2.25 million estimate.” The report also highlighted that Aegis expects further acceleration through 2017.
Highlights from the report include the growth of CytoSorb sales of 13,000 units, the fact that REFRESH 1 met its safety endpoint, and that CytoSorbents has $6.4 million in cash with $5 million available from its credit facility with Bridge Bank. As a result, the company expects to have enough funding for its operations through the second half of 2017.
CytoSorbents’ Q3 2016 sales report is not the only aspect of the company’s recent success. In November of this year, CTSO announced the addition of Belgium and Luxembourg to its direct sales directories, expanding its distribution to include 42 countries around the world. These new additions will allow CytoSorbents to target these focused markets with its own direct sales force.
For more information, visit the company’s website at www.cytosorbents.com
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.net
